171 related articles for article (PubMed ID: 35349682)
1. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
[TBL] [Abstract][Full Text] [Related]
2. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.
Binder MT; Becker E; Wiendl M; Schleier L; Fuchs F; Leppkes M; Atreya R; Neufert C; Atreya I; Neurath MF; Zundler S
Inflamm Bowel Dis; 2018 May; 24(6):1237-1250. PubMed ID: 29788362
[TBL] [Abstract][Full Text] [Related]
3. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
4. α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.
Melde M; Müller TM; Schneider I; Geppert CI; Mühl L; Besendorf L; Allner C; Becker E; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
Therap Adv Gastroenterol; 2021; 14():17562848211054707. PubMed ID: 34868349
[TBL] [Abstract][Full Text] [Related]
5. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
6. MAdCAM-1 Costimulates T Cells through Integrin α
DeBerg HA; Konecny AJ; Shows DM; Lord JD
Immunohorizons; 2022 Mar; 6(3):211-223. PubMed ID: 35273097
[TBL] [Abstract][Full Text] [Related]
7. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
Lamb CA; O'Byrne S; Keir ME; Butcher EC
J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab.
Moens A; van Hoeve K; Humblet E; Rahier JF; Bossuyt P; Dewit S; Franchimont D; Macken E; Nijs J; Posen A; Strubbe B; Van Hootegem A; Van Moerkercke W; Vermeire S; Ferrante M;
J Crohns Colitis; 2019 Jan; 13(1):12-18. PubMed ID: 30281093
[TBL] [Abstract][Full Text] [Related]
9. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease).
Grant AJ; Lalor PF; Hübscher SG; Briskin M; Adams DH
Hepatology; 2001 May; 33(5):1065-72. PubMed ID: 11343233
[TBL] [Abstract][Full Text] [Related]
10. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis.
Besendorf L; Müller TM; Geppert CI; Schneider I; Mühl L; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
Therap Adv Gastroenterol; 2022; 15():17562848221098899. PubMed ID: 35784193
[TBL] [Abstract][Full Text] [Related]
12. MAdCAM-1/α4β7 Integrin-Mediated Lymphocyte/Endothelium Interactions Exacerbate Acute Immune-Mediated Hepatitis in Mice.
Schippers A; Hübel J; Heymann F; Clahsen T; Eswaran S; Schlepütz S; Püllen R; Gaßler N; Tenbrock K; Tacke F; Wagner N
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1227-1250.e1. PubMed ID: 33316453
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease.
Schneider I; Allner C; Mühl L; Melde M; Lissner D; Mantzivi E; Glauben R; Vitali F; Becker E; Atreya I; Müller TM; Atreya R; Siegmund B; Neurath MF; Zundler S
Transl Res; 2023 Mar; 253():8-15. PubMed ID: 36272713
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
15. Blocking integrin α
Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
[TBL] [Abstract][Full Text] [Related]
16. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
17. The Underappreciated Role of Secretory IgA in IBD.
Bamias G; Kitsou K; Rivera-Nieves J
Inflamm Bowel Dis; 2023 Aug; 29(8):1327-1341. PubMed ID: 36943800
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
[TBL] [Abstract][Full Text] [Related]
19. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
20. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
